BioCentury | Dec 16, 2019
Clinical News

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

...share price profoundly. Gossamer has said it believes GB001 is differentiated from fevipiprant; at the BofA Merrill Lynch...
BioCentury | Oct 22, 2019
Clinical News

Novartis still bullish on asthma program despite pair of Phase III misses

...GB001 in moderate to severe eosinophilic asthma, with final results due in 2H20. At the BofA Merrill Lynch...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Top shareholders include New Enterprise Associates, Novartis Venture Fund, Novo Holdings A/S and Sofinnova Investments. BofA Merrill Lynch...
BioCentury | Oct 12, 2019
Financial News

As newly public biotechs stumble out of gate, 89bio, Centogene join IPO queue

...company 89bio Inc. proposed to raise up to $70 million in an offering underwritten by BofA Merrill Lynch...
BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

...over $1 billion in its history as a private company. BioNTech’s underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

...small molecule immunomodulators. Its majority shareholder remains the Strüngmann family office. Underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...lymphoma are expected in 2Q20 and 4Q21, respectively. The offering is underwritten by Morgan Stanley, BofA Merrill Lynch...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...Ugur Sahin holds almost 19%, while MIG Fonds has about 6%. Underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...cells within their spatial context across a tissue sample. Underwriters are J.P. Morgan, Goldman Sachs, BofA Merrill Lynch...
BioCentury | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

...are Foresite Capital Management, Venrock, Paladin Capital and Fidelity. Underwriters are J.P. Morgan, Goldman Sachs, BofA Merrill Lynch...
Items per page:
1 - 10 of 737
BioCentury | Dec 16, 2019
Clinical News

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

...share price profoundly. Gossamer has said it believes GB001 is differentiated from fevipiprant; at the BofA Merrill Lynch...
BioCentury | Oct 22, 2019
Clinical News

Novartis still bullish on asthma program despite pair of Phase III misses

...GB001 in moderate to severe eosinophilic asthma, with final results due in 2H20. At the BofA Merrill Lynch...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Top shareholders include New Enterprise Associates, Novartis Venture Fund, Novo Holdings A/S and Sofinnova Investments. BofA Merrill Lynch...
BioCentury | Oct 12, 2019
Financial News

As newly public biotechs stumble out of gate, 89bio, Centogene join IPO queue

...company 89bio Inc. proposed to raise up to $70 million in an offering underwritten by BofA Merrill Lynch...
BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

...over $1 billion in its history as a private company. BioNTech’s underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

...small molecule immunomodulators. Its majority shareholder remains the Strüngmann family office. Underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...lymphoma are expected in 2Q20 and 4Q21, respectively. The offering is underwritten by Morgan Stanley, BofA Merrill Lynch...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...Ugur Sahin holds almost 19%, while MIG Fonds has about 6%. Underwriters are J.P. Morgan, BofA Merrill Lynch...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...cells within their spatial context across a tissue sample. Underwriters are J.P. Morgan, Goldman Sachs, BofA Merrill Lynch...
BioCentury | Aug 20, 2019
Financial News

Aug. 19 Financial Quick Takes: Juvenescence raises $100M Series B; plus 10X, IGM propose IPOs

...are Foresite Capital Management, Venrock, Paladin Capital and Fidelity. Underwriters are J.P. Morgan, Goldman Sachs, BofA Merrill Lynch...
Items per page:
1 - 10 of 737